NARCAN NASAL SPRAY Rx
Generic Name and Formulations:
Naloxone HCl 4mg; per spray; contains benzalkonium chloride.
Indications for NARCAN NASAL SPRAY:
Reversal of known or suspected opioid overdose, including respiratory and/or CNS depression.
Adults and Children:
Give as single spray intranasally into one nostril. May give additional doses (using a new nasal spray) every 2–3 mins in alternate nostrils if unresponsive or relapses into respiratory depression. Seek immediate emergency medical assistance after the first dose.
Not a substitute for emergency medical care. Known or suspected opioid dependence; abrupt reversal may precipitate acute withdrawal syndrome. Monitor patients with satisfactory response due to long duration of some narcotics. Post-op use in pre-existing cardiac disease. Have other resuscitative measures available. Elderly. Pregnancy; monitor for neonatal withdrawal symptoms. Nursing mothers.
Caution with cardiotoxic drugs. Incomplete reversal of buprenorphine or pentazocine; may require higher naloxone dose.
Increased BP, musculoskeletal pain, headache, nasal effects (eg, dryness, edema, congestion, inflammation); opioid withdrawal.
Single-dose nasal spray—2
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|